PCM
EW icon

Presidio Capital Management’s Edwards Lifesciences EW Stock Holding History

Presidio Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,792
Closed -$295K – 77
2025
Q3 		$295K Sell
3,792
-1,000
-21% -$78.1K 0.1% 50
2025
Q2 		$375K Sell
4,792
-1,315
-22% -$98.1K 0.14% 44
2025
Q1 		$443K Buy
6,107
+22
+0.4% +$1.57K 0.18% 36
2024
Q4 		$450K Sell
6,085
-1,907
-24% -$133K 0.24% 40
2024
Q3 		$527K Buy
+7,992
New +$581K 0.34% 34

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Presidio Capital Management's EW Position: Q4 2025 in Review

Presidio Capital Management sold out of Edwards Lifesciences (EW) in Q4 2025, closing a stake of 3,792 shares — an estimated $295K sold.

Presidio Capital Management first reported a position in EW in Q3 2024 and held it in 5 quarters. The position peaked at $527K in Q3 2024. 1,313 funds tracked by Wall St. Rank hold EW as of Q4 2025.

  • Presidio Capital Management reported no remaining Edwards Lifesciences position as of Q4 2025 after selling out during the quarter.
  • Presidio Capital Management sold 3,792 Edwards Lifesciences shares in Q4 2025, an estimated $295K.
  • Presidio Capital Management first reported a position in Edwards Lifesciences in Q3 2024 and held it in 5 quarters.
  • Presidio Capital Management's Edwards Lifesciences position peaked at $527K in Q3 2024.
  • 1,313 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2025.

Based on Presidio Capital Management's 13F filing for Q4 2025, filed 15 Jan 2026.